TriSalus Life Sciences, Inc.
TLSI
$5.49
$0.244.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.97% | 12.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.97% | 12.41% | |||
| Cost of Revenue | 22.94% | 21.12% | |||
| Gross Profit | 8.90% | 11.03% | |||
| SG&A Expenses | -12.70% | 46.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.18% | 22.56% | |||
| Operating Income | 21.38% | -33.23% | |||
| Income Before Tax | -2.58% | -320.86% | |||
| Income Tax Expenses | 600.00% | 66.67% | |||
| Earnings from Continuing Operations | -2.64% | -321.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.64% | -321.34% | |||
| EBIT | 21.38% | -33.23% | |||
| EBITDA | 21.60% | -33.70% | |||
| EPS Basic | 1.69% | -227.24% | |||
| Normalized Basic EPS | 16.32% | -251.12% | |||
| EPS Diluted | 1.69% | -227.24% | |||
| Normalized Diluted EPS | 16.32% | -251.12% | |||
| Average Basic Shares Outstanding | 3.54% | 3.96% | |||
| Average Diluted Shares Outstanding | 3.54% | 3.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||